Pharmaceutical

Janssen’s BALVERSA receives EC approval for metastatic urothelial carcinoma

The European Commission (EC) has approved Janssen's BALVERSA as a treatment for adults with unresectable or metastatic urothelial carcinoma.

Aug 27, 2024 - 04:00
Janssen’s BALVERSA receives EC approval for metastatic urothelial carcinoma
The European Commission (EC) has approved Janssen's BALVERSA as a treatment for adults with unresectable or metastatic urothelial carcinoma.
Read the original article

Tags:

Previous Article

China NMPA grants approval for GenFleet’s fulzerasib to treat lung cancer

Next Article

Germany to Provide 100,000 Mpox Vaccine Doses to Combat Outbreak in Africa

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

After failed FSGS bid, Travere wins full FDA approval for Filspari in IgAN

After failed FSGS bid, Travere wins full FDA approval f...

Sep 8, 2024

FDA authorizes Novavax’s updated Covid-19 vaccine

FDA authorizes Novavax’s updated Covid-19 vaccine

Oct 4, 2023

US Elections: how healthcare could look under a Harris or Trump administration

US Elections: how healthcare could look under a Harris ...

Oct 20, 2024